KRAS Lung Cancer Drug: Overcoming Resistance
Summary of the Article: New Drug Combination Shows Promise Against KRAS-Mutant Lung Cancer
This article discusses a new research breakthrough from the University of Michigan regarding the treatment of KRAS-mutant Non-Small Cell Lung Cancer (NSCLC). Here’s a breakdown of the key points:
* The Problem: KRAS mutations are present in about 30% of NSCLC cases, leading to poor prognoses and limited treatment options. Existing drugs like adagrasib and trametinib, while initially effective, often face resistance development.
* The Discovery: Researchers found that adagrasib and trametinib actually destabilize a protein complex called protein Phosphatase 2A (PP2A), which normally suppresses lung cancer development. This destabilization appears to be a key driver of resistance.
* The solution: The team developed a new drug, RPT04402, which acts as a “molecular glue” to stabilize the PP2A complex.
* the Results: Combining RPT04402 with existing KRAS inhibitors (adagrasib and trametinib) in lab studies and mouse models:
* Restored PP2A function.
* Triggered cancer cell death.
* Substantially shrank tumors.
* Delayed the onset of resistance – extending treatment effectiveness to over 150 days in mouse models.
* Slowed cancer cell proliferation and enhanced apoptosis in both cell lines and patient-derived models.
* Meaning: This research suggests that restoring PP2A activity could be a crucial strategy to overcome resistance to current KRAS-targeted therapies in NSCLC.
In essence, the study identifies a mechanism of resistance to existing drugs and proposes a novel combination therapy to address it, offering hope for improved treatment outcomes for patients with KRAS-mutant NSCLC.